Open AccessThe era of immuno-oncology in onco-urology: what have we achieved?
The review of the symposium of the alliance between Merck and Pfizer held within the framework of the XXV Russian Oncology Congress. November 9, 2021
Author(s) -
Editorial Board
Publication year - 2021
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2021.4.201315
Subject(s) - javelin , medicine , avelumab , urothelial cancer , oncology , clinical oncology , bladder cancer , urothelial carcinoma , immunotherapy , cancer , nivolumab , mechanical engineering , engineering , throwing
On November 9, 2021 in the framework of the XXV Russian Oncology Congress the symposium was held where the various issues of approaches of drug treatment and surgical treatment of metastatic renal cell carcinoma and urothelial cancer were discussed. New drugs are being appeared, large clinical studies are being conducted, new prospects for immunotherapy of malignant neoplasms are being developed, nowadays. One of the new options is immune checkpoint inhibitors. In the framework of the symposium were presented the results of two trials the JAVELIN Renal 101 and the JAVELIN Bladder 100, showing the efficacy and safety of the PD-L1 inhibitor avelumab. The symposium was supported by the alliance between Merck and Pfizer.